drugset / Trial / NCT04098770

Summary

Combined antiretroviral therapy (ART) efficiently suppresses viral replication and markedly decreases mortality among patients with HIV-1 infection/AIDS. While the advanced AIDS patients with CD4+T cell count less than 200 cells/µL often develop seriously opportunistic infections (OIs), severe wasting syndrome, and other fatal complications, which are the major causes of death in these patients. There has been no effective immune therapy for advanced AIDS patients who had a high mortality rate even in the era of cART. This clinical trail is to inspect the efficiency of allogeneic adoptive immune therapy for advanced AIDS patients.

Timeline

Start
2019-10-11
Primary completion
2023-12-30
Completion
2024-12-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Allogeneic Adoptive Immune Therapy Cell therapy 1e+08 cells/kg Intravenous
Subject Allogeneic Adoptive Immune Therapy Cell therapy 3e+08 cells/kg Intravenous

Indications